Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

1 terminated/withdrawn out of 2 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(50.0%)
N/A
1(50.0%)
2Total
Phase 3(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT02651844Not ApplicableCompleted

Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.

Role: lead

NCT00536003Phase 3Terminated

Vaginal Progesterone to Prevent Preterm Delivery in Women With Preterm Labor

Role: collaborator

All 2 trials loaded